Cellular bone matrices: viable stem cell-containing bone graft substitutes
Skovrlj B., Guzman JZ., Al Maaieh M., Cho SK., Iatridis JC., Qureshi SA.
Narrative Review on Back & Spine, published in Spine J (2014) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Spine J (2014)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 24929059
- PMCID
- PMC4402977
- DOI
- 10.1016/j.spinee.2014.05.024
- Citations
- 48
Abstract (original English)
Background context Advances in the field of stem cell technology have stimulated the development and increased use of allogenic bone grafts containing live mesenchymal stem cells (MSCs), also known as cellular bone matrices (CBMs). It is estimated that CBMs comprise greater than 17% of all bone grafts and bone graft substitutes used. Purpose To critically evaluate CBMs, specifically their technical specifications, existing published data supporting their use, US Food and Drug Administration (FDA) regulation, cost, potential pitfalls, and other aspects pertaining to their use. Study design Areview of literature. Methods A series of Ovid, Medline, and Pubmed-National Library of Medicine/National Institutes of Health (www.ncbi.nlm.nih.gov) searches were performed. Only articles in English journals or published with English language translations were included. Level of evidence of the selected articles was assessed. Specific technical information on each CBM was obtained by direct communication from the companies marketing the individual products. Results Five different CBMs are currently available for use in spinal fusion surgery. There is a wide variation between the products with regard to the average donor age at harvest, total cellular concentration, percentage of MSCs, shelf life, and cell viability after defrosting. Three retrospective studies evaluating CBMs and fusion have
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewEurope PMC
Stem cell therapy for degenerative disc disease: A systematic review of preclinical evidence, clinical translation, and future directions
Systematic Review on Back Pain, Disc Degeneration, published in N Am Spine Soc J (2026) — summary generated from the PubMed abstract.
- 2026
N Am Spine Soc J - Level AMeta-analysisEurope PMC
Association between platelet to lymphocyte ratio and the risk of vertebral fracture in patients with osteoporosis: a systematic review and meta-analysis
Meta-analysis on Back & Spine, published in Front Endocrinol (Lausanne) (2026) — summary generated from the PubMed abstract.
- 2026
Front Endocrinol (Lausanne) - Level ASystematic ReviewEurope PMC
The Role of Exosome-miRNA as Biomarkers of Alzheimer's Disease: A Systematic Review of Case-Control and Longitudinal Studies
Systematic Review with a reported sample of 3046 on Neuroinflammation, published in Actas Esp Psiquiatr (2026) — summary generated from the PubMed abstract.
- 2026
- n = 3046
Actas Esp Psiquiatr - Level AMeta-analysisEurope PMC
Platelet-Rich Plasma vs. Mesenchymal Stem Cells for Lumbar Disc Degeneration: A Systematic Review and Meta-Analysis
Meta-analysis on Disc Degeneration, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci - Level ASystematic ReviewPubMed
Host immune determinants of stromal vascular fraction graft survival: Toward a concept of SVF therapy resistance - A systematic narrative review.
Systematic Review on Spinal Cord Injury, Chronic Inflammation, Immune Modulation, published in Cell Transplant (2026) — summary generated from the PubMed abstract.
- 2026
Cell Transplant - Level AMeta-analysisPubMed
Stem cell-derived exosome treatment for acute spinal cord injury: a systematic review and meta-analysis based on preclinical evidence.
Meta-analysis on Spinal Cord Injury, published in Front Neurol (2025) — summary generated from the PubMed abstract.
- 2025
Front Neurol